Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Proteros Biostructures GmbH is a Germany-based, privately-held company specializing in integrated structure-based drug discovery. They offer a comprehensive suite of services, including protein production and purification, X-ray crystallography, biophysical interaction analysis (SPR, ITC, DSF/nanoDSF, MST), fragment-based lead discovery (FBLD), and medicinal chemistry for lead optimization. Proteros supports pharmaceutical and biotech companies worldwide by providing high-quality structural information and hit-to-lead services to accelerate drug development programs. The company leverages its proprietary technologies and expertise in areas like membrane proteins and challenging targets. In 2021, Proteros was acquired by WuXi AppTec.
The headquarters serves as the central hub for research and development, laboratory operations, corporate administration, and client project management for its global drug discovery services.
State-of-the-art laboratories equipped for protein sciences, X-ray crystallography, biophysical screening, and computational chemistry. Its location within the IZB (Innovation and Start-up Center for Biotechnology) in Martinsried provides access to a vibrant scientific community and infrastructure.
The work culture at Proteros is highly scientific, collaborative, and innovation-focused, driven by a team of experienced researchers and technicians dedicated to advancing drug discovery projects. Emphasis is placed on precision, quality, and scientific rigor.
The Martinsried headquarters is significant due to its advanced R&D capabilities and its position within one of Europe's leading biotech clusters, fostering innovation and collaboration.
Proteros Biostructures GmbH operates globally, serving clients in the pharmaceutical and biotechnology sectors across Europe, North America, and Asia from its main research facilities in Germany. Its specialized services in structure-based drug discovery, including protein production, crystallography, biophysical analysis, and lead generation, support drug discovery programs worldwide. The US office in San Diego enhances its ability to serve the North American market.
Bunsenstr. 7a
Martinsried/Planegg
Bavaria
Germany
Address: 10578 Science Center Drive, Suite 150, San Diego, CA 92121
To strengthen Proteros' presence in the significant North American market, foster collaborations with US-based companies, and provide local support for ongoing projects.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Proteros Biostructures GmbH' leadership includes:
Proteros Biostructures GmbH has been backed by several prominent investors over the years, including:
No major C-level executive hires or exits have been publicly announced for Proteros Biostructures GmbH in the last 12 months. The leadership team appears stable following its acquisition by WuXi AppTec in 2021.
Discover the tools Proteros Biostructures GmbH uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Proteros Biostructures GmbH likely utilizes common corporate email formats. Based on typical German company structures and individuals listed on their website or LinkedIn, common patterns include [first_initial][last_name]@proteros.com or [first_name].[last_name]@proteros.com.
[first_initial][last_name]@proteros.com or [first_name].[last_name]@proteros.com
Format
tneuefeind@proteros.com or gerhard.mueller@proteros.com
Example
80%
Success rate
WuXi AppTec • May 19, 2021
WuXi AppTec announced its acquisition of Proteros Biostructures GmbH, a Germany-based contract research organization renowned for its expertise in structure-based drug discovery. This acquisition aims to enhance WuXi AppTec's capabilities in hit generation and lead optimization....more
European Pharmaceutical Review • October 26, 2023
Proteros Biostructures and Evariste Galois have entered a collaboration to combine Proteros’ structure-based drug discovery platform with Evariste Galois’ AI technology (Generative AI: GAI) for novel drug design. The goal is to accelerate the identification and optimization of new drug candidates....more
Proteros Biostructures GmbH (via LinkedIn) • September 1, 2022
Proteros announced the expansion of its Cryo-Electron Microscopy (Cryo-EM) capabilities, further strengthening its structural biology platform to support drug discovery for complex protein targets. This enhancement allows for high-resolution structure determination of challenging molecules....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Proteros Biostructures GmbH, are just a search away.